Closing Plenary: Fundraising in the New Capital Market Environment

  • Recommend
  • Tweet
  • Print
  • Email

Tuesday, February 11, 4:00 p.m. - 4:55 p.m. | Astor

2013 was clearly the year of the IPO. As a result, a dynamic fundraising environment emerged last year. Many biotechs took full advantage of this market to raise capital - through follow-ons and PIPEs after their initial debut. What’s next? What challenges will await these newly public companies in 2014, or those private biotechs waiting in the wings? Hear industry experts discuss why the markets are doing well and what effect it has had on the entire biotech ecosystem. What’s their advice on how can we keep the momentum, and what do biotech CEOs need to look out for in 2014?

Moderator

  • Jonathan L. Kravetz, Chair of the Securities Practice Group, Mintz Levin

Panelists

  • David-Alexandre Gros, MD, Executive Vice President, Chief Strategy Officer, Sanofi
  • Michael Margolis, R.Ph., Managing Director, ROTH Capital Partners
  • Ed Mathers, Partner, New Enterprise Associates 
  • Dennis Purcell, Senior Managing Partner, Aisling Capital

Who's Who

David-Alexandre Gros

David-Alexandre Gros, MD
Executive Vice President, Chief Strategy Officer, Sanofi

David-Alexandre Gros holds a B.A. from Dartmouth College (1995), an M.D. from Johns Hopkins University School of Medicine (1999) and an M.B.A. from Harvard Business School (2002). He worked in clinical and health outcomes research at the Department of Urology of the Johns Hopkins Hospital from 1996 to 1999, and then as a Resident Physician at the University of Pennsylvania Health System from 1999 to 2000.

In 2002, David-Alexandre Gros joined McKinsey & Company’s Pharmaceuticals & Medical Products practice as an Associate, was promoted to Engagement Manager in 2004, and to Associate Principal in 2006. In late 2006, he joined Merrill Lynch as a Vice President in Healthcare Investment Banking focusing on strategy, mergers & acquisitions and corporate finance until joining Centerview Partners in mid-2009 as a Principal and founding member of the Healthcare Investment Banking Division.

He was appointed to his present position in September 2011.

 

Jonathan L. Kravetz
Chair of the Securities Practice Group, Mintz Levin

Jon is Chair of the Securities Practice Group and one of the core members of the Life Sciences Practice Group. He represents clients in both public and privately placed equity and debt financings under the Securities Act of 1933, provides counseling for public companies with respect to the full range of securities compliance issues under the Securities Exchange Act of 1934, and advises high-technology, biotechnology, and medical device companies in numerous contractual and strategic matters. Jon has an active international practice, representing European companies in merger and acquisition, financing, and other transactions with US and non-US companies.

He has extensive knowledge and experience in the public offering process, representing companies and underwriters in both initial and follow-on public offerings involving straight equity, debt securities, and hybrid securities, such as convertible exchangeable preferred stock, underwritten by major national, international, and regional underwriting firms with domestic and foreign tranches.

He also represents and counsels companies, both public and private, in merger and acquisition transactions, venture capital financings, and executive compensation issues.

Michael Margolis, R.Ph
Managing Director, ROTH Capital Partners

Michael Margolis is a Managing Director in ROTH Capital Partners’ Healthcare Investment Banking group and joined the firm in December 2009. Margolis was most recently a Managing Director of Healthcare Investment Banking at Merriman Curhan Ford. Previously Margolis was a senior vice president at Rodman & Renshaw. He had extensive financial and pharmaceutical industry experience before joining Rodman. Margolis worked at Novartis Pharmaceuticals Corporation in several roles, including as a director in the global business development and licensing group. He was an equity research analyst at Ursus Capital, and he began his career as at Eli Lilly & Company as a senior pharmaceutical representative.

Margolis is a registered pharmacist with an M.B.A. from New York University’s Stern School of Business and a pharmacy degree from Rutgers University, College of Pharmacy. He is based in our New York office.

Ed Mathers
Partner, New Enterprise Associates

Ed Mathers joined NEA as a Partner in August 2008 after spending 26 years working within the pharmaceutical/biotechnology industry in a variety of senior roles. Ed is focused on biotechnology and specialty pharmaceuticals investments, and is a director of Envisia Therapeutics, Liquidia Technologies, Mirna Therapeutics, Ra Pharmaceuticals, and Rhythm Pharmaceuticals. Previously, Ed was a director of Plexxikon prior to its sale to Daiichi Sankyo. Ed is also a member of the Biotechnology Industry Organization (BIO) board, Southeast Bio board, and the NC State Physical and Mathematical Sciences Foundation board.

Immediately prior to joining NEA, Ed served as Executive Vice President, Corporate Development and Venture, at MedImmune, Inc., and was a director of MedImmune, LLC. In this role, he was a member of the leadership team that executed the sale of the company to Astra Zeneca for $15.6 billion in 2007. While at MedImmune, Ed was responsible for the company’s corporate and business development activities and led the company’s venture capital subsidiary, MedImmune Ventures, Inc. Before joining MedImmune in 2002, he served as Vice President, Marketing and Corporate Licensing and Acquisitions at Inhale Therapeutic Systems (now Nektar). Previously, Ed spent 15 years at Glaxo Wellcome, Inc. (GlaxoSmithKline), where he held sales and marketing positions of increasing responsibility. He earned his bachelor's degree in chemistry from North Carolina State University.

Dennis Purcell
Senior Managing Partner, Aisling Capital

Mr. Purcell has served as the Senior Managing Director of Aisling Capital since February 2000 and is responsible for the management of the Partnership. The Partnership has approximately $1.7 billion of assets under management and has invested in over seventy-five companies across three funds since its inception.

Prior to joining Aisling Capital, Mr. Purcell served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist, “H&Q”) and was a member of the Operating Committee. While at Hambrecht & Quist, he was directly involved with over two hundred completed transactions and supervised over $10 billion of financing and advisory assignments in the pharmaceutical, biotechnology, and medical products industries. During his tenure, BioWorld and other industry publications cited H&Q as the leading underwriter of life sciences securities. Prior to joining H&Q, Mr. Purcell was a Managing Director in the Healthcare Group at PaineWebber, Inc.

Mr. Purcell currently has served on the Board of Directors of numerous public and private companies. He is also a member of the Board of the Life Sciences Foundation, L.E.K. consulting and a Special Advisor to Poliwogg Holdings, Inc. He has previously served on the Boards of the Biotechnology Industry Organization, the New York Biotechnology Association, the Irvington Institute, and was a member of the Advisory Council of Harvard Medical School.